News
Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...
Small doses of the involuntary nervous system blocker, atropine, may offer a non-invasive treatment for symptomatic vitreous ...
On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...
Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...
Approximately 48% patients who develop symptomatic COVID-19 either fail to recover or achieve only partial recovery within 6 to 18 months after infection, according to data derived from Hastie CE ...
BOSTON — More patients with early symptomatic Alzheimer’s disease reached amyloid clearance and plaque reductions at 6 months with donanemab vs. aducanumab, according to a presentation at the ...
The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS, July 25 ...
The results demonstrated that symptomatic individuals had, on average, higher viral loads than those who were presymptomatic or asymptomatic, thereby suggesting that they are more infectious.
Whether the population of untreated severe symptomatic AS patients was as large as Brennan had estimated from claims data is also unclear. Speaking with TCTMD, David Cohen, MD (University of ...
Pre-symptomatic spread is the transmission of the virus by people who don’t look or feel sick, but will eventually get symptoms later. They, too, can infect others without knowing it.
FDA agreed that PolTREG’s clinical data in Stage 3 Type 1 Diabetes (T1D) appears sufficient to support the Prospect of Direct benefit in an adaptive Phase 2/3 study of PTG-007 in Stage 1 and Stage 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results